Potent, selective and competitive ATM kinase inhibitor (Ki
= 2.2 nM, IC50
values are 13, 2500, 9300, 16600, > 100000 and > 100000 nM at ATM, DNA-PK, mTOR, PI 3-kinase, PI 4-K and ATR respectively). Decreases viability of MCF-7, A549 and HCT116 cells and decreases p21CIP1
levels in vitro
. Acts as a radio- and chemosensitizer for the treatment of cancer.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
Hickson I, Zhao Y, Richardson CJ et al.
Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: Implications for chemotherapy.
Crescenzi et al.
Clin.Cancer Res., 2008;14:1877
Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis.
Eaton et al.
The citations listed below are publications that use Tocris products. Selected citations for KU 55933 include:
Showing Results 1 - 10 of 37